Ontario Institute for Cancer Research (under maintenance)
FFPE tissue block available; select number of patients must have accessible disease suitable for biopsy. ECOG 0 or 1. At least 1 prior line of cytotoxic chemotherapy for breast cancer, in any setting, must have included anthracycline and taxane. No limit to number of prior regimens.
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. It is not yet known whether zoledronate is more effective than clodronate or ibandronate in treating breast cancer. Patients are randomized to 1 of 3 treatment arms.